Takhzyro
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Lanadelumab
- Used in
- Blood, clotting and anaemia
- Made by
- Takeda Pharmaceuticals International AG Ireland Branch
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Takeda Pharmaceuticals International AG Ireland Branch |
|---|---|
| Active substance | Lanadelumab |
| Used in | Blood, clotting and anaemia |
| Classification | B06AC05 · Blood, clotting and anaemia |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2018-11-22 |
| Last updated by the regulator | 2026-08-03 |
| EMA product number | EMEA/H/C/004806 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).